{
    "organizations": [],
    "uuid": "f17b9a5ea2c213e12f7765ae506fbcbd8401a0cf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-immupharma-announces-topline-resul/brief-immupharma-announces-topline-results-of-lupuzor-pivotal-phase-iii-trial-idUSFWN1RU01E",
    "ord_in_thread": 0,
    "title": "BRIEF-Immupharma Announces Topline Results Of Lupuzor Pivotal Phase III Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17 (Reuters) - ImmuPharma PLC:\n* LUPUZOR DEMONSTRATED SUPERIOR RESPONSE RATE OVER PLACEBO IN PRIMARY ANALYSIS ON FULL ANALYSIS SET OF ALL 202 PATIENTS\n* SUPERIOR RESPONSE DID NOT ALLOW STATISTICAL SIGNIFICANCE TO BE REACHED (P = 0.2631) AND TRIALâ€™S PRIMARY END POINT WAS NOT MET\n* IN PATIENTS WHO HAD ANTI-DSDNA AUTOANTIBODIES LUPUZOR DEMONSTRATED A SUPERIOR RESPONSE RATE OVER PLACEBO\n* STUDY CONFIRMED SAFETY PROFILE OF LUPUZOR WITH ZERO SERIOUS ADVERSE EVENTS REPORTED Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-17T15:58:00.000+03:00",
    "crawled": "2018-04-18T18:24:04.022+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "immupharma",
        "plc",
        "lupuzor",
        "demonstrated",
        "superior",
        "response",
        "rate",
        "placebo",
        "primary",
        "analysis",
        "full",
        "analysis",
        "set",
        "patient",
        "superior",
        "response",
        "allow",
        "statistical",
        "significance",
        "reached",
        "p",
        "trial",
        "primary",
        "end",
        "point",
        "met",
        "patient",
        "autoantibody",
        "lupuzor",
        "demonstrated",
        "superior",
        "response",
        "rate",
        "placebo",
        "study",
        "confirmed",
        "safety",
        "profile",
        "lupuzor",
        "zero",
        "serious",
        "adverse",
        "event",
        "reported",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}